PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29100435-2	2017	Experimental Design: IL-6 was disrupted by transcription activator-like effector nucleases (TALEN) in HCCLM3 cells, and was used to evaluate the role of IL-6 on tumor cell proliferation, apoptosis, invasion and key signaling pathways involved in sorafenib and/or IFNalpha therapy.	Sorafenib	246-255	interleukin 6	Homo sapiens	21-25	
29100435-4	2017	IL-6 could attenuate the anti-proliferation effect by sorafenib and combination therapy but facilitate the pro-apoptosis of the combination therapy and augment the pro-invasive effect induced by single treatment.	Sorafenib	54-63	interleukin 6	Homo sapiens	0-4	
29100435-5	2017	IL-6 could down-regulate p-STAT3, however up-regulate the p-MEK/p-ERK and NF-kB/iNOS expression, and it also facilitated the promotion on p-JAK2 and p-MEK/p-ERK by either sorafenib or IFN-alpha.	Sorafenib	171-180	interleukin 6	Homo sapiens	0-4	
29100435-9	2017	Sorafenib and combination therapies are suitable for HCC cells with low or no IL-6 expression confirmed in vivo study.	Sorafenib	0-9	interleukin 6	Homo sapiens	78-82